AudioEye Appoints Dr. Gallin as CMO to Enhance AI in Retinal Diagnostics
- AEYE Health appoints Dr. Pamela F. Gallin as Chief Medical Officer to enhance AI in retinal diagnostics.
- Dr. Gallin will lead the expansion of AEYE-DS, a device for quick diabetic retinopathy screenings.
- AEYE Health aims to improve eye care accessibility and patient outcomes, especially in underserved communities.
Dr. Pamela F. Gallin Joins AEYE Health as Chief Medical Officer to Advance AI in Retinal Diagnostics
AEYE Health, a pioneering company in AI-powered retinal diagnostics, announces the appointment of Dr. Pamela F. Gallin as its new Chief Medical Officer. With over 43 years of experience in ophthalmology, Dr. Gallin brings a wealth of knowledge and expertise to the organization. Her previous roles include Clinical Professor of Ophthalmology at Columbia University Medical Center and Director Emeritus of Pediatric Ophthalmology at NewYork-Presbyterian. Globally recognized for her contributions to the field, Dr. Gallin has authored an international textbook and two advocacy books, solidifying her status as a leader in ophthalmic education and care.
Dr. Gallin's extensive background aligns seamlessly with AEYE Health’s mission to prevent blindness and enhance patient outcomes through innovative technology. Central to this mission is AEYE-DS, the company's groundbreaking device designed for diabetic retinopathy screening. This FDA-cleared solution allows for on-the-spot AI-driven eye exams, requiring only a single image per eye and eliminating the need for dilation. Such features make AEYE-DS not only the fastest-growing solution for diabetic eye exams in the United States but also accessible in diverse care settings. As the prevalence of diabetic retinopathy rises, Dr. Gallin’s leadership is expected to catalyze the rapid expansion of this transformative product.
In her new role, Dr. Gallin expresses enthusiasm for the potential impact of AEYE-DS, particularly in underserved communities where access to eye care is limited. By bridging critical care gaps, AEYE Health aims to prevent blindness on a large scale, reflecting Dr. Gallin's commitment to improving patient care. CEO Zack Dvey-Aharon highlights her clinical acumen and dedication to advancing healthcare as pivotal for the company's growth. With Dr. Gallin at the helm of medical strategy, AEYE Health is set to redefine the landscape of eye care through AI technology, ultimately enhancing accessibility and outcomes for patients nationwide.
In addition to Dr. Gallin's appointment, AEYE Health continues to focus on the integration of advanced technologies in healthcare. The innovative capabilities of AEYE-DS exemplify the company's commitment to leveraging AI to streamline diagnostic processes, paving the way for a new era in ophthalmology. As the company positions itself for future growth, the emphasis on improving patient accessibility remains a cornerstone of its strategy, particularly for those at risk for vision loss.
With a strong leadership team and a groundbreaking product, AEYE Health is well-equipped to address the challenges of diabetic retinopathy screening and the broader needs of eye care.